Persistent high on-treatment platelet reactivity in acute coronary syndrome

Journal of Thrombosis and Thrombolysis

Volumn 33, Issue 3, 2012, Pages 267-273

  Lynch, Donald R ^a   Khan, Farooq H ^a   Vaidya, Dhananjay ^a   Williams, Marlene S ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Acute coronary syndrome; Aspirin response; Platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DUAL SPECIFICITY PHOSPHATASE 2; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PADGEM PROTEIN; ARACHIDONIC ACID;

ACUTE CORONARY SYNDROME; ADRENERGIC STIMULATION; ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEALTH STATUS; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PERSISTENT HIGH ON TREATMENT PLATELET REACTIVITY; PLATELET REACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THORAX PAIN; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE POOR PLASMA; TREATMENT OUTCOME; AGED; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; MIDDLE AGED; PHYSIOLOGY; THROMBOCYTE ACTIVATION;

ACUTE CORONARY SYNDROME; AGED; ARACHIDONIC ACID; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION; TREATMENT OUTCOME;

EID: 84871695898     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0678-x     Document Type: Article

References (24)

1. Kottke-Marchant K (2009) Importance of platelets and platelet response in acute coronary syndromes. Cleve Clin J Med 76(Suppl 1):S2-S7
2. Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF (2008) Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events-a meta-analysis. Int J Cardiol 128(2):166-171
3. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV (2007) Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch Intern Med 167(15): 1593-1599
4. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF (2010) High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 104(2):279-286
5. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56(12):919-933
6. Edlund A, Berglund B, van Dorne D, Kaijser L, Nowak J, Patrono C, Sollevi A, Wennmalm A (1985) Coronary flow regulation in patients with ischemic heart disease: Release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation. Circulation 71(6):1113-1120
7. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD (1994) Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25(12): 2331-2336
8. Muir AR, McMullin MF, Patterson C, McKeown PP (2009) Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart 95(15):1225-1229
9. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F (2004) Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43(6):979-984
10. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davi G, Patrono C (2009) Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: Implications for aspirin "resistance". J Am Coll Cardiol 53(8):667-677
11. Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD (2009) Association of cyclooxygenase-1-dependent and-independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 120(25): 2586-2596
12. Williams MS, Kickler TS, Vaidya D, Ng'alla LS, Bush DE (2006) Evaluation of platelet function in aspirin treated patients with CAD. J Thromb Thrombolysis 21(3):241-247
13. Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF (2005) Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 106(8):2723-2729
14. Christie DJ, Kottke-Marchant K, Gorman RT (2008) Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 19(2):104-110
15. Kempfert J, Anger K, Rastan A, Krabbes S, Lehmann S, Garbade J, Sauer M, Walther T, Dhein S, Mohr FW (2009) Postoperative development of aspirin resistance following coronary artery bypass. Eur J Clin Invest 39(9):769-774
16. Kennon S, Price CP, Mills PG, Macey M, Cooper J, Clarke H, Timmis AD (2003) The central role of platelet activation in determining the severity of acute coronary syndromes. Heart 89(10):1253-1254
17. Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabate M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R (2009) Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: Results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 119(25):3215-3222
18. Patti G, Fossati C, Manzoli A, D'Ambrosio A, Abbate A, Montesanti R, Di Sciascio G (2000) Platelet glycoprotein IIBIIIA receptor inhibitors in patients with ischemic heart disease. Clin Ter 151(4):301-306
19. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57(25):2474-2483
20. Wagner DD (2005) New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 25(7):1321-1324
21. Gurbel PA, Kereiakes DJ, Serebruany VL (2000) Soluble P-selectin is not a surrogate marker for platelet P-selectin: Evidence from a multicenter chest pain study group. J Thromb Thrombolysis 10(1):15-22
22. Cheng G, Shan J, Xu G, Liu P, Zhou Y, Zhu Y, Lu X (2007) Relationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease. J Clin Pharm Ther 32(3):287-292
23. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41(6):961-965
24. Atiemo AD, Ng'Alla LS, Vaidya D, Williams MS (2008) Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain. J Thromb Thrombolysis 25(2):173-178